339 related articles for article (PubMed ID: 8324616)
1. GnRH analogues for contraception.
Fraser HM
Br Med Bull; 1993 Jan; 49(1):62-72. PubMed ID: 8324616
[TBL] [Abstract][Full Text] [Related]
2. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
Behre HM; Nashan D; Hubert W; Nieschlag E
J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
[TBL] [Abstract][Full Text] [Related]
3. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
Tom L; Bhasin S; Salameh W; Steiner B; Peterson M; Sokol RZ; Rivier J; Vale W; Swerdloff RS
J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
[TBL] [Abstract][Full Text] [Related]
4. Developments in the control of testicular function.
Swerdloff RS; Wang C; Bhasin S
Baillieres Clin Endocrinol Metab; 1992 Apr; 6(2):451-83. PubMed ID: 1377467
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of ovulation: comparison between the mechanism of action of steroids and GnRH analogues.
Bouchard P; Wolf JP; Hajri S
Hum Reprod; 1988 May; 3(4):503-6. PubMed ID: 3292571
[TBL] [Abstract][Full Text] [Related]
6. Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido.
Pavlou SN; Brewer K; Farley MG; Lindner J; Bastias MC; Rogers BJ; Swift LL; Rivier JE; Vale WW; Conn PM
J Clin Endocrinol Metab; 1991 Dec; 73(6):1360-9. PubMed ID: 1955518
[TBL] [Abstract][Full Text] [Related]
7. Novel peptides in ovarian follicular fluid: implications for contraceptive development.
Schwartz NB
Res Front Fertil Regul; 1982 Sep; 2(2):1-11. PubMed ID: 12179632
[TBL] [Abstract][Full Text] [Related]
8. Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates.
Biljan MM; Mahutte NG; Dean N; Hemmings R; Bissonnette F; Tan SL
Fertil Steril; 1998 Dec; 70(6):1063-9. PubMed ID: 9848296
[TBL] [Abstract][Full Text] [Related]
9. Luteinizing hormone-releasing hormone (LHRH) and its analogs for contraception in women: a review.
Thau RB
Contraception; 1984 Feb; 29(2):143-62. PubMed ID: 6426857
[TBL] [Abstract][Full Text] [Related]
10. Clinical applications of gonadotropin-releasing hormone and gonadotropin-releasing hormone analogs.
Yen SS
Fertil Steril; 1983 Mar; 39(3):257-66. PubMed ID: 6130985
[TBL] [Abstract][Full Text] [Related]
11. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens.
Bagatell CJ; Matsumoto AM; Christensen RB; Rivier JE; Bremner WJ
J Clin Endocrinol Metab; 1993 Aug; 77(2):427-32. PubMed ID: 8345047
[TBL] [Abstract][Full Text] [Related]
12. Single-dose administration of the gonadotropin-releasing hormone antagonist, Nal-Lys (antide) to healthy men.
Bagatell CJ; Conn PM; Bremner WJ
Fertil Steril; 1993 Oct; 60(4):680-5. PubMed ID: 8405525
[TBL] [Abstract][Full Text] [Related]
13. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
[TBL] [Abstract][Full Text] [Related]
14. Reversible inhibition of testicular function by a gonadotropin hormone-releasing hormone antagonist in monkeys (Macaca fascicularis).
Weinbauer GF; Surmann FJ; Akhtar FB; Shah GV; Vickery BH; Nieschlag E
Fertil Steril; 1984 Dec; 42(6):906-14. PubMed ID: 6389185
[TBL] [Abstract][Full Text] [Related]
15. Gonadotropin-releasing hormone antagonist plus testosterone: a potential male contraceptive.
Bremner WJ; Bagatell CJ; Steiner RA
J Clin Endocrinol Metab; 1991 Sep; 73(3):465-9. PubMed ID: 1874925
[TBL] [Abstract][Full Text] [Related]
16. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
[TBL] [Abstract][Full Text] [Related]
17. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist.
Ruchhoft EA; Elkind-Hirsch KE; Malinak R
Fertil Steril; 1996 Jul; 66(1):54-60. PubMed ID: 8752611
[TBL] [Abstract][Full Text] [Related]
18. New knowledge in the physiology of hormonal contraceptives.
Lobo RA; Stanczyk FZ
Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1499-507. PubMed ID: 8178898
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment with an oral contraceptive is effective in reducing the incidence of functional ovarian cyst formation during pituitary suppression by gonadotropin-releasing hormone analogues.
Biljan MM; Mahutte NG; Dean N; Hemmings R; Bissonnette F; Tan SL
J Assist Reprod Genet; 1998 Nov; 15(10):599-604. PubMed ID: 9866068
[TBL] [Abstract][Full Text] [Related]
20. Suppression of corpus luteum function by the gonadotropin-releasing hormone antagonist Nal-Glu: effect of the dose and timing of human chorionic gonadotropin administration.
Dubourdieu S; Charbonnel B; Massai MR; Marraoui J; Spitz I; Bouchard P
Fertil Steril; 1991 Sep; 56(3):440-5. PubMed ID: 1894021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
